KR20000057315A - 항원-특이적 ＩｇＭ 검출방법 - Google Patents
항원-특이적 ＩｇＭ 검출방법 Download PDFInfo
- Publication number
- KR20000057315A KR20000057315A KR1019990704759A KR19997004759A KR20000057315A KR 20000057315 A KR20000057315 A KR 20000057315A KR 1019990704759 A KR1019990704759 A KR 1019990704759A KR 19997004759 A KR19997004759 A KR 19997004759A KR 20000057315 A KR20000057315 A KR 20000057315A
- Authority
- KR
- South Korea
- Prior art keywords
- antibody
- binding
- binding partner
- antibodies
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108091007433 antigens Proteins 0.000 title claims abstract description 72
- 102000036639 antigens Human genes 0.000 title claims abstract description 72
- 239000000427 antigen Substances 0.000 title claims abstract description 70
- 238000001514 detection method Methods 0.000 title abstract description 13
- 230000027455 binding Effects 0.000 claims abstract description 123
- 238000000034 method Methods 0.000 claims abstract description 50
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 33
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 33
- 239000000178 monomer Substances 0.000 claims abstract description 26
- 230000000694 effects Effects 0.000 claims abstract description 24
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 10
- 238000012360 testing method Methods 0.000 claims description 42
- 239000007790 solid phase Substances 0.000 claims description 31
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 230000009870 specific binding Effects 0.000 claims description 13
- 239000003550 marker Substances 0.000 claims description 11
- 239000000654 additive Substances 0.000 claims description 8
- 229960002685 biotin Drugs 0.000 claims description 8
- 235000020958 biotin Nutrition 0.000 claims description 8
- 239000011616 biotin Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 238000003018 immunoassay Methods 0.000 claims description 6
- 108090001008 Avidin Proteins 0.000 claims description 4
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 4
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 4
- 108010090804 Streptavidin Proteins 0.000 claims description 4
- 239000000941 radioactive substance Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 108090001090 Lectins Proteins 0.000 claims description 2
- 102000004856 Lectins Human genes 0.000 claims description 2
- 230000001745 anti-biotin effect Effects 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000002523 lectin Substances 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 239000004332 silver Substances 0.000 claims 1
- 229940072221 immunoglobulins Drugs 0.000 abstract description 15
- 210000001124 body fluid Anatomy 0.000 abstract description 3
- 239000010839 body fluid Substances 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 45
- 239000000523 sample Substances 0.000 description 37
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 239000007787 solid Substances 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000010998 test method Methods 0.000 description 11
- 150000001413 amino acids Chemical group 0.000 description 10
- 238000005406 washing Methods 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 150000002632 lipids Chemical group 0.000 description 7
- 239000007791 liquid phase Substances 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000012876 carrier material Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000004816 latex Substances 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000011895 specific detection Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 230000003302 anti-idiotype Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010061041 Chlamydial infection Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108091065810 E family Proteins 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 108090001030 Lipoproteins Chemical group 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 108091005996 glycated proteins Proteins 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical group 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/825—Pretreatment for removal of interfering factors from sample
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19649389A DE19649389A1 (de) | 1996-11-29 | 1996-11-29 | Antigenspezifischer IgM-Nachweis |
| DE19649389.7 | 1996-11-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20000057315A true KR20000057315A (ko) | 2000-09-15 |
Family
ID=7813066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019990704759A Withdrawn KR20000057315A (ko) | 1996-11-29 | 1997-11-26 | 항원-특이적 ＩｇＭ 검출방법 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6489129B1 (enExample) |
| EP (1) | EP0944832B1 (enExample) |
| JP (1) | JP3958797B2 (enExample) |
| KR (1) | KR20000057315A (enExample) |
| CN (1) | CN1245560A (enExample) |
| AR (1) | AR009638A1 (enExample) |
| AT (1) | ATE204082T1 (enExample) |
| AU (1) | AU720123B2 (enExample) |
| BR (1) | BR9714365A (enExample) |
| CA (1) | CA2272302A1 (enExample) |
| DE (2) | DE19649389A1 (enExample) |
| ES (1) | ES2162347T3 (enExample) |
| IL (1) | IL130112A0 (enExample) |
| NO (1) | NO992579L (enExample) |
| NZ (1) | NZ335754A (enExample) |
| TW (1) | TW434405B (enExample) |
| WO (1) | WO1998023955A2 (enExample) |
| ZA (1) | ZA9710726B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10009503A1 (de) * | 2000-02-29 | 2001-08-30 | Roche Diagnostics Gmbh | Verfahren zur Immobilisierung von Konjugaten in diagnostischen Tests |
| US7105311B2 (en) * | 2001-05-03 | 2006-09-12 | Immunetics, Inc. | Systems and methods for detection of analytes in biological fluids |
| US7262019B2 (en) * | 2001-05-03 | 2007-08-28 | Immunetics, Inc. | System and methods for detection of Bacillus anthracis related analytes in biological fluids |
| US7387890B2 (en) | 2004-12-16 | 2008-06-17 | Chembio Diagnostic Systems, Inc. | Immunoassay devices and use thereof |
| US7189522B2 (en) | 2005-03-11 | 2007-03-13 | Chembio Diagnostic Systems, Inc. | Dual path immunoassay device |
| WO2006098804A2 (en) | 2005-03-11 | 2006-09-21 | Chembio Diagnostic Systems, Inc. | Dual path immunoassay device |
| DK2112158T3 (da) | 2007-04-20 | 2012-01-23 | Hoffmann La Roche | Påvisning af primære infektioner med patogener |
| US20100022916A1 (en) | 2008-07-24 | 2010-01-28 | Javanbakhsh Esfandiari | Method and Apparatus for Collecting and Preparing Biological Samples for Testing |
| EP3187585A1 (en) | 2010-03-25 | 2017-07-05 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
| US8603835B2 (en) | 2011-02-10 | 2013-12-10 | Chembio Diagnostic Systems, Inc. | Reduced step dual path immunoassay device and method |
| ES2667425T3 (es) | 2011-06-10 | 2018-05-10 | Oregon Health & Science University | Glucoproteínas y vectores recombinantes de CMV |
| AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
| EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
| CN102507932A (zh) * | 2011-12-02 | 2012-06-20 | 无锡博慧斯生物医药科技有限公司 | 一种IgM抗体检测试纸条 |
| EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
| US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
| US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| PE20170259A1 (es) | 2014-04-02 | 2017-04-14 | Chembio Diagnostic Systems Inc | Inmunoensayo que utiliza un conjugado de captura |
| US20160116466A1 (en) | 2014-10-27 | 2016-04-28 | Chembio Diagnostic Systems, Inc. | Rapid Screening Assay for Qualitative Detection of Multiple Febrile Illnesses |
| US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3176580A1 (en) | 2015-12-01 | 2017-06-07 | Roche Diagnostics GmbH | Method for reduction of interferences in immunoassays |
| CN105759059A (zh) * | 2016-04-27 | 2016-07-13 | 丹娜（天津）生物科技有限公司 | 一种检测EV71病毒IgM抗体的免疫检测试剂盒及其制备方法 |
| CN105974111B (zh) * | 2016-07-20 | 2019-07-09 | 国家纳米科学中心 | 一种类风湿因子(IgM型)及其他抗原特异性IgM抗体联合检测的方法 |
| CN107656057A (zh) * | 2017-09-06 | 2018-02-02 | 中国农业科学院兰州兽医研究所 | 一种用于检测布鲁氏杆菌病IgM抗体的ELISA试剂盒及其应用 |
| CN112585468B (zh) * | 2018-09-18 | 2024-09-24 | 美国西门子医学诊断股份有限公司 | 用于寨卡病毒免疫测定的方法和试剂 |
| CN113495141A (zh) * | 2020-03-20 | 2021-10-12 | 迈克生物股份有限公司 | 2019新型冠状病毒IgM抗体检测试剂盒 |
| CN119505004A (zh) * | 2023-08-22 | 2025-02-25 | 重庆艾生斯生物工程有限公司 | 抗rf的抗体或其功能性片段及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL80129A0 (en) * | 1986-09-23 | 1986-12-31 | Savyon Diagnostics Ltd | Method for the determination of igm and iga immunoglobulins and reagents therefor |
| DE3705686C2 (de) * | 1987-02-23 | 1995-11-30 | Boehringer Mannheim Gmbh | Verfahren zur Bestimmung von Antikörpern |
| SE8701628D0 (sv) * | 1987-04-16 | 1987-04-16 | Erling Norrby | Medel for analys mm |
| DE3717401A1 (de) * | 1987-05-23 | 1988-12-08 | Behringwerke Ag | Einschritt-immuntest zur bestimmung von antigen-spezifischen antikoerpern aus einer der immunglobulin-klassen a, m, d oder e und dazu geeignetes mittel |
| FI970301A7 (fi) | 1994-07-25 | 1997-03-24 | Roche Diagnostics Gmbh | Spesifisen immunoglobuliinin määrittäminen käyttäen useampaa antigeeni a |
| CN100478352C (zh) * | 1994-07-25 | 2009-04-15 | 罗切诊断学有限公司 | 半抗原标记的肽 |
| DE4439452A1 (de) * | 1994-11-04 | 1996-05-09 | Boehringer Mannheim Gmbh | Antikörperklassenspezifisches Entstörungsreagenz |
-
1996
- 1996-11-29 DE DE19649389A patent/DE19649389A1/de not_active Withdrawn
-
1997
- 1997-11-24 TW TW086117602A patent/TW434405B/zh active
- 1997-11-26 CA CA002272302A patent/CA2272302A1/en not_active Abandoned
- 1997-11-26 AT AT97953700T patent/ATE204082T1/de not_active IP Right Cessation
- 1997-11-26 CN CN97181480A patent/CN1245560A/zh active Pending
- 1997-11-26 KR KR1019990704759A patent/KR20000057315A/ko not_active Withdrawn
- 1997-11-26 AU AU57513/98A patent/AU720123B2/en not_active Ceased
- 1997-11-26 JP JP52427598A patent/JP3958797B2/ja not_active Expired - Lifetime
- 1997-11-26 IL IL13011297A patent/IL130112A0/xx unknown
- 1997-11-26 BR BR9714365A patent/BR9714365A/pt not_active Application Discontinuation
- 1997-11-26 US US09/319,084 patent/US6489129B1/en not_active Expired - Lifetime
- 1997-11-26 EP EP97953700A patent/EP0944832B1/de not_active Expired - Lifetime
- 1997-11-26 NZ NZ335754A patent/NZ335754A/en unknown
- 1997-11-26 ES ES97953700T patent/ES2162347T3/es not_active Expired - Lifetime
- 1997-11-26 WO PCT/EP1997/006583 patent/WO1998023955A2/de not_active Ceased
- 1997-11-26 DE DE59704261T patent/DE59704261D1/de not_active Expired - Lifetime
- 1997-11-27 AR ARP970105577A patent/AR009638A1/es unknown
- 1997-11-28 ZA ZA9710726A patent/ZA9710726B/xx unknown
-
1999
- 1999-05-28 NO NO992579A patent/NO992579L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU720123B2 (en) | 2000-05-25 |
| JP2001506749A (ja) | 2001-05-22 |
| CA2272302A1 (en) | 1998-06-04 |
| NO992579L (no) | 1999-07-28 |
| TW434405B (en) | 2001-05-16 |
| EP0944832A2 (de) | 1999-09-29 |
| WO1998023955A3 (de) | 1998-07-23 |
| EP0944832B1 (de) | 2001-08-08 |
| JP3958797B2 (ja) | 2007-08-15 |
| ZA9710726B (en) | 1999-05-28 |
| DE19649389A1 (de) | 1998-06-04 |
| DE59704261D1 (de) | 2001-09-13 |
| NZ335754A (en) | 2001-05-25 |
| ES2162347T3 (es) | 2001-12-16 |
| AU5751398A (en) | 1998-06-22 |
| NO992579D0 (no) | 1999-05-28 |
| CN1245560A (zh) | 2000-02-23 |
| US6489129B1 (en) | 2002-12-03 |
| IL130112A0 (en) | 2000-06-01 |
| WO1998023955A2 (de) | 1998-06-04 |
| ATE204082T1 (de) | 2001-08-15 |
| AR009638A1 (es) | 2000-04-26 |
| BR9714365A (pt) | 2000-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6489129B1 (en) | Antigen-specific IgM detection | |
| US6645732B2 (en) | Antigen-specific IgG detection | |
| EP0615129B1 (en) | Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis or primary sclerosing cholangitis | |
| JP4270751B2 (ja) | 全血用クロマトグラフィーデバイス内のポリカチオンの中和 | |
| US4292403A (en) | Detection and/or determination of IgM, IgA, IgD and IgE immunoglobulins | |
| EP0345462B1 (en) | Immunoassay for HIV-1 antigens using F(AB')2 fragments as probe | |
| FI89984B (fi) | Enstegsimmuntest foer bestaemning av antigenspecifika antikroppar hoerande till immunoglobulingruppen a, m, d eller e och medel daerfoer | |
| US4894347A (en) | Erythrocyte agglutination assay | |
| JPS59208463A (ja) | ルミネツセント標識を含む固相イムノアツセイ法 | |
| JP4130505B2 (ja) | Ｄ−アミノ酸からなるペプチドによる診断方法の干渉の排除 | |
| US6489131B1 (en) | Interference reduction by rheumatoid factors | |
| EP0345277B1 (en) | Analyte detection in particulate-containing samples | |
| JPH1078435A (ja) | 被検物質の免疫化学的測定における感度の上昇 | |
| CA1148858A (en) | Determination of immunoglobulins | |
| CA2008100A1 (en) | Method for the determination of immunologically detectable substance | |
| JPH0658937A (ja) | 被検体の免疫化学的測定方法 | |
| CA1339006C (en) | Self-contained multi-immunoassay diagnostic system | |
| EP0756173A1 (en) | Reagent for detecting substances and method for diagnosing rheumatoid arthritis | |
| JPH10319017A (ja) | 蛍光エネルギー転移を利用した物質の測定方法およびそのための試薬 | |
| KR940008091B1 (ko) | 리간드의 면역학적 검출방법 | |
| MXPA99004991A (es) | Deteccion de antigenos especificos para la inmunoglobulina clase m | |
| US5180664A (en) | Washing solution, which contains a complexing agent for metal ions, for a solid-phase immunometric method, and the use thereof | |
| AU612760B2 (en) | Enzyme immunoassay for detecting hiv antigens in human sera | |
| MXPA99004995A (en) | ANTIGEN-SPECIFIC IgG DETECTION | |
| CA1281285C (en) | Immunoassay using antibody-antigen conjugates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 19990529 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |